Nura Bio Reports Preclinical Data Validating a Conserved Mechanism of Inhibition of NAD Hydrolases Implicated in Neurodegeneration in Neuron
Retrieved on:
Tuesday, September 13, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Other Health, Lists of diseases, NAD, Hope, SARM1, Hydrolase, Hydrolysis, MS, Vance DeGeneres, Nura, Nerve injury, CD38, Biology, Bratkowski, TBI, Neuroprotection, Doctor of Philosophy, Diagnosis, ALS, Research, Neurological disorder, CIPN, Founding, Pharmaceutical industry, Neuron
Deploying high-resolution structures and sophisticated mechanistic models, our scientific team at Nura Bio has validated a conserved, NAD-dependent mechanism of inhibition of NAD hydrolases like SARM1 and CD38 as a viable therapeutic strategy for neuroprotection, said Shilpa Sambashivan, PhD, lead author and Chief Scientific Officer at Nura Bio.
Key Points:
- Deploying high-resolution structures and sophisticated mechanistic models, our scientific team at Nura Bio has validated a conserved, NAD-dependent mechanism of inhibition of NAD hydrolases like SARM1 and CD38 as a viable therapeutic strategy for neuroprotection, said Shilpa Sambashivan, PhD, lead author and Chief Scientific Officer at Nura Bio.
- Since its conception in 2018, Nura Bio has been steadily growing a differentiated, small molecule pipeline focused on targets implicated in driving axon degeneration and neuroinflammation in neurological diseases.
- Nura Bios lead program, the SARM1 inhibitor program is currently in IND-enabling studies with the goal of entering First-in-Human trials in early 2023.
- At Nura Bio we envision a world where the diagnosis of a neurological disorder comes with the hope of a cure.